Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs
about
sameAs
The antithrombotic profile of aspirin. Aspirin resistance, or simply failure?Adverse drug reactions and drug-drug interactions with over-the-counter NSAIDsThe emerging role of oxylipins in thrombosis and diabetesGiving aspirin and ibuprofen after myocardial infarctionAspirin resistanceReview article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessmentMeloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteersInteractions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis modelImpact of nonsteroidal antiinflammatory drugs on the cardioprotective effects of aspirinCurrent use of nonsteroidal antiinflammatory drugs and the risk of acute myocardial infarctionThe effect of single-dose naproxen on eicosanoid formation in human gastroduodenal mucosaInfluence of aspirin or heparin on platelet function and postoperative blood loss after coronary artery bypass surgeryNon-steroidal antiinflammatory drugs and the risk of acute myocardial infarctionIs there an interaction between the cardiovascular protective effects of low-dose aspirin and ibuprofen?Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategiesPrimer: managing NSAID-induced ulcer complications--balancing gastrointestinal and cardiovascular risksRelationship between endothelial dysfunction, oxidant stress and aspirin resistance in patients with stable coronary heart diseaseCardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actionsThe impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitorAspirin resistance in coronary artery disease is correlated to elevated markers for oxidative stress but not to the expression of cyclooxygenase (COX) 1/2, a novel COX-1 polymorphism or the PlA(1/2) polymorphismRecent advance in antiplatelet therapy: the mechanisms, evidence and approach to the problemsIncreased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugsCardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib50th anniversary of the discovery of ibuprofen: an interview with Dr Stewart AdamsSafe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risksBiological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities.Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly.Safety of nonsteroidal antiinflammatory drugs in patients with cardiovascular disease.Migraine and cardiovascular disease in women and the role of aspirin: subgroup analyses in the Women's Health Study.Searching for factors associated with resistance to acetylsalicylic acid used for secondary prevention of strokeAn evidence-based update on nonsteroidal anti-inflammatory drugs.Approach to managing musculoskeletal pain: acetaminophen, cyclooxygenase-2 inhibitors, or traditional NSAIDs?Heart failure in the oldest patients: the impact of comorbid conditions.Harmful effects of NSAIDs among patients with hypertension and coronary artery diseaseSelective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice?Minimizing risks of NSAIDs: cardiovascular, gastrointestinal and renal.Aspirin resistance: disparities and clinical implications.The interaction of ibuprofen and diclofenac with aspirin in healthy volunteers.Prospective, observational study of antiplatelet and coagulation biomarkers as predictors of thromboembolic events after implantation of ventricular assist devices.
P2860
Q24794673-A31E0B04-81FB-472F-83E1-AF3CDAF5F207Q26800279-78FED5BF-3BAE-4487-B872-069936FE94EBQ26823893-5304EDFA-602D-4DF7-A0B1-78D2DB9B5D4BQ28166360-545C7E53-C261-48B4-A858-5A016441450FQ28167475-9EEED80F-7ADA-48C3-907F-35D334783563Q28168612-BEF1452D-E8A7-4407-B6B9-61A1F768F9C5Q28168971-54B5398F-9172-4E35-ABCC-1A2026A356DEQ28171150-FD2FA2BD-42E3-4697-AA5E-16BB02497C67Q28174778-DEE0CFE4-21E0-406D-B514-559D5F729DC2Q28181807-C53FCECB-168F-4BE5-82CA-869AD31706D8Q28194351-FA34864B-4945-4D2B-80E1-E00396DECD17Q28195148-12C449F1-FF01-4F9B-86B7-D97ED3844090Q28196509-86C5324D-AD6E-4F34-AEBE-B78197FA48D0Q28196511-019402F7-7A2C-473A-9B0A-4292B814447BQ28200569-5D57B7C2-33A5-451E-81A7-60FCB3304B74Q28200571-FF56EA02-3CDC-4F4B-B20A-46C60593F49DQ28210092-E2C02385-DEF3-449E-8DE6-E70CB0528C67Q28210559-1540EC87-8FAE-4D80-B577-C73B2A12BD48Q28211940-12EB51E4-EC93-4E23-B2D2-7DF9213CC0B1Q28217400-535D6C38-1921-41F8-B084-C998B2D0EC2FQ28217995-75FEAA91-14C8-42AC-919F-93065B00DC86Q28218351-C1D77848-832F-4650-B61F-BCC44520DFEAQ28218432-FF3B654C-4A49-4616-867A-97B151644363Q28222097-DA7888C4-7249-4091-9C90-6D8099BC66AAQ28253389-536E9675-D495-465D-A88F-9C79BCB2D3C4Q30629677-AF11B404-BCB7-498D-9EBA-03D27D3CABE9Q34245387-761B4A70-2801-457C-8501-52E8C7D4A349Q34463743-CE398925-AF80-4B19-9D84-E0188FF83E8AQ34474985-CDD464B6-4D55-41F7-AC05-052661173C84Q35127126-47E32B3E-476D-4707-A112-9EF2D4812221Q35232269-D30C06A5-2EB4-4D25-9442-E25379316788Q35758411-22019593-D49C-47BB-8B3E-BA3C8EDF380BQ35942177-B1C7FA44-BDE9-405D-BEC6-A2CDDE3CA846Q36123475-A71D5142-D49E-4FC8-BB55-0206FAF2129FQ36332332-8F664C0C-14DE-4C20-98A1-259EB6EE68BDQ36645806-866A8586-C767-4A96-B2D4-8D24BA0A5F06Q36673018-49BA97CB-C8C5-49AA-B876-22032C16A881Q37227512-8535EA02-7D11-4C0A-A8C2-C19FE99238D7Q37332627-7C3FDFD9-B7F6-4D1E-B790-3F4B8A8C4E2AQ37479004-4897BD14-F805-4AA7-BF80-6E1BA5C2461E
P2860
Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Inhibition of clinical benefit ...... eroidal antiinflammatory drugs
@ast
Inhibition of clinical benefit ...... eroidal antiinflammatory drugs
@en
Inhibition of clinical benefit ...... eroidal antiinflammatory drugs
@nl
type
label
Inhibition of clinical benefit ...... eroidal antiinflammatory drugs
@ast
Inhibition of clinical benefit ...... eroidal antiinflammatory drugs
@en
Inhibition of clinical benefit ...... eroidal antiinflammatory drugs
@nl
prefLabel
Inhibition of clinical benefit ...... eroidal antiinflammatory drugs
@ast
Inhibition of clinical benefit ...... eroidal antiinflammatory drugs
@en
Inhibition of clinical benefit ...... eroidal antiinflammatory drugs
@nl
P2093
P50
P1433
P1476
Inhibition of clinical benefit ...... eroidal antiinflammatory drugs
@en
P2093
Alexander M Walker
Charles H Hennekens
J Michael Gaziano
Robert J Glynn
P304
P356
10.1161/01.CIR.0000087593.07533.9B
P407
P577
2003-09-09T00:00:00Z